A citation-based method for searching scientific literature


List of co-cited articles
844 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E Kahn, Steven M Haffner, Mark A Heise, William H Herman, Rury R Holman, Nigel P Jones, Barbara G Kravitz, John M Lachin, M Colleen O'Neill, Bernard Zinman,[...]. N Engl J Med 2006
4

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Juris J Meier, Baptist Gallwitz, Stefan Salmen, Oliver Goetze, Jens J Holst, Wolfgang E Schmidt, Michael A Nauck. J Clin Endocrinol Metab 2003
254
4

ISEC: a program to calculate insulin secretion.
R Hovorka, P A Soons, M A Young. Comput Methods Programs Biomed 1996
133
4

Hypoglycemia in diabetes.
Philip E Cryer, Stephen N Davis, Harry Shamoon. Diabetes Care 2003
736
4

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
4

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.
Richard M Bergenstal, William V Tamborlane, Andrew Ahmann, John B Buse, George Dailey, Stephen N Davis, Carol Joyce, Tim Peoples, Bruce A Perkins, John B Welsh,[...]. N Engl J Med 2010
508
4

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
4

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
192
4

GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
J Schirra, M Nicolaus, H J Woerle, C Struckmeier, M Katschinski, B Göke. Neurogastroenterol Motil 2009
52
7

Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Stuart A Weinzimer, Jennifer L Sherr, Eda Cengiz, Grace Kim, Jessica L Ruiz, Lori Carria, Gayane Voskanyan, Anirban Roy, William V Tamborlane. Diabetes Care 2012
89
4

Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes.
Vera Zdravkovic, Jill K Hamilton, Denis Daneman, Elizabeth A Cummings. J Pediatr 2006
32
12


Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
756
4

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
731
4

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen. BMJ Open 2015
9
44

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Keith C Ferdinand, William B White, David A Calhoun, Eva M Lonn, Philip T Sager, Rocco Brunelle, Honghua H Jiang, Rebecca J Threlkeld, Kenneth E Robertson, Mary Jane Geiger. Hypertension 2014
82
4


Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
160
4

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
149
4



Amylin concentrations and glucose control.
J E Koda, M Fineman, T J Rink, G E Dailey, D B Muchmore, L G Linarelli. Lancet 1992
136
4

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Ingrid M Libman, Kellee M Miller, Linda A DiMeglio, Kathleen E Bethin, Michelle L Katz, Avni Shah, Jill H Simmons, Michael J Haller, Sripriya Raman, William V Tamborlane,[...]. JAMA 2015
96
4

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
Anne Nissen, Mikkel Christensen, Filip K Knop, Tina Vilsbøll, Jens J Holst, Bolette Hartmann. J Clin Endocrinol Metab 2014
73
5

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
300
4


Expression of the GLP-1 receptor in mouse, rat, and human pancreas.
Ditte Tornehave, Peter Kristensen, John Rømer, Lotte Bjerre Knudsen, R Scott Heller. J Histochem Cytochem 2008
167
3

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Juris J Meier, Michael A Nauck, Andrea Pott, Kai Heinze, Oliver Goetze, Kerem Bulut, Wolfgang E Schmidt, Baptist Gallwitz, Jens J Holst. Gastroenterology 2006
171
3

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
Filip K Knop, Tina Vilsbøll, Patricia V Højberg, Steen Larsen, Sten Madsbad, Aage Vølund, Jens J Holst, Thure Krarup. Diabetes 2007
214
3

Circulating glucagon after total pancreatectomy in man.
J J Holst, J H Pedersen, F Baldissera, F Stadil. Diabetologia 1983
74
4



GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.
Yang Z De Marinis, Albert Salehi, Caroline E Ward, Quan Zhang, Fernando Abdulkader, Martin Bengtsson, Orit Braha, Matthias Braun, Reshma Ramracheya, Stefan Amisten,[...]. Cell Metab 2010
171
3

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
Kyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, Hong Yan Zhang, Diane M Bodenmiller, Amy L Cox, Steven J Jacobs, Julie S Moyers, Rebecca A Owens, Aaron D Showalter,[...]. J Clin Invest 2004
156
3

Impaired regulation of the incretin effect in patients with type 2 diabetes.
Jonatan I Bagger, Filip K Knop, Asger Lund, Henrik Vestergaard, Jens J Holst, Tina Vilsbøll. J Clin Endocrinol Metab 2011
132
3




Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
Nicole A Sherry, Wei Chen, Jake A Kushner, Mariela Glandt, Qizhi Tang, Sue Tsai, Pere Santamaria, Jeffrey A Bluestone, Anne-Marie B Brillantes, Kevan C Herold. Endocrinology 2007
138
3

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
3

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Diane K Wherrett, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks,[...]. Lancet 2011
226
3


Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
3

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
Wilma L Suarez-Pinzon, Robert F Power, Yanhua Yan, Clive Wasserfall, Mark Atkinson, Alex Rabinovitch. Diabetes 2008
132
3


Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
J Rosenstock, C Aguilar-Salinas, E Klein, S Nepal, J List, R Chen. Curr Med Res Opin 2009
236
3



Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men.
N Geary, H R Kissileff, F X Pi-Sunyer, V Hinton. Am J Physiol 1992
95
3

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Gary A Herman, Arthur Bergman, Catherine Stevens, Paul Kotey, Bingming Yi, Peng Zhao, Bruno Dietrich, George Golor, Andreas Schrodter, Bart Keymeulen,[...]. J Clin Endocrinol Metab 2006
379
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.